Sigmoidoscopy as an evidence-based colorectal cancer screening – a possible option?

Sigmoidoscopy as an evidence-based colorectal cancer screening – a possible option? - SIGMO

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00019010

Enrollment

940

Registered

2019-11-18

Start date

2020-04-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C18 C19 C20

Interventions

Group 1: One-time survey in April/May 2020 of 50- to 60 years old statutory insured persons with a written, self administered questionnaire consisting of a) sociodemographic and health-related items,

Eligibility

Sex/Gender

All

Age

50 Years to 60 Years

Inclusion criteria

Inclusion criteria: 50- to 60 years old statutory insured persons

Exclusion criteria

Exclusion criteria: Statutory insured persons with diagnosed colorectal cancer, statutory insured persons with a diagnosed bowel disease that is associated with an increased risk for colorectal cancer (e.g. ulcerative colitis or Crohn's disease)

Design outcomes

Primary

Measure	Time frame
Primary outcome (first project phase - discrete-choice experiment): Estimating the contribution of attributes and levels to overall utility (part-worth utilities). Primary outcome (second project phase - decision analytic modelling): Cost-effectiveness of an extended screening strategy (iFOBT, colonoscopy, sigmoidoscopy) compared to the current colorectal cancer screening program (iFOBT, colonoscopy).	—

Measure

Time frame

Primary outcome (first project phase - discrete-choice experiment): Estimating the contribution of attributes and levels to overall utility (part-worth utilities). Primary outcome (second project phase - decision analytic modelling): Cost-effectiveness of an extended screening strategy (iFOBT, colonoscopy, sigmoidoscopy) compared to the current colorectal cancer screening program (iFOBT, colonoscopy).

—

Secondary

Measure	Time frame
Secondary outcomes (first project phase - discrete-choice experiment): 1. The (hypothetical) colorectal cancer screening method that is preferred by statutory insured persons. 2. Estimation of the relevance of different attributes of colorectal cancer screening methods to overall utility. Secondary outcomes (second project phase - decision analytic modelling): 1. Effects (e.g. detection rate of colorectal cancer and adenomas, colorectal cancer incidence and mortality, life years gained (LYG), quality adjusted life years (QALY)). 2. Determination of costs that are associated with the extended screening program.	—

Measure

Time frame

Secondary outcomes (first project phase - discrete-choice experiment): 1. The (hypothetical) colorectal cancer screening method that is preferred by statutory insured persons. 2. Estimation of the relevance of different attributes of colorectal cancer screening methods to overall utility. Secondary outcomes (second project phase - decision analytic modelling): 1. Effects (e.g. detection rate of colorectal cancer and adenomas, colorectal cancer incidence and mortality, life years gained (LYG), quality adjusted life years (QALY)). 2. Determination of costs that are associated with the extended screening program.

—

Countries

Germany

Contacts

Public ContactMelanie Brinkmann

Medizinische Hochschule Hannover (MHH) Institut für Epidemiologie, Sozialmedizin und Gesundheitssystemforschung

Brinkmann.Melanie2@mh-hannover.de+49 511 532-6826

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 16, 2026